Table 2.
Results of infectious screening assays (blood)
| Infectious Agent | Assay | Pre-COVID Donors | Pre-COVID Recipients | Post-COVID Donors | Post-COVID Recipients | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seropositive rate | Seronegative rate | n | Seropositive rate | Seronegative rate | n | Seropositive rate | Seronegative rate | n | Seropositive rate | Seronegative rate | n | ||
| Blood | |||||||||||||
| Cytomegalovirus (CMV) | CMV IgG | 35.7% | 64.3% | 28 | 41.2% | 58.8% | 17 | 3.7% | 96.3% | 27 | 0.0% | 100.0% | 1 |
| Epstein Barr virus (EBV) | EBV IgG and IgM | 96.4% | 3.6% | 28 | 100.0% | 0.0% | 17 | 81.5% | 18.5% | 27 | 100.0% | 0.0% | 1 |
| Entameba histolytica | E. histolytica IgG | 3.6% | 96.4% | 28 | 0.0% | 100.0% | 17 | 22.2% | 77.8% | 27 | 0.0% | 100.0% | 1 |
| Hepatitis A virus (HAV) | HAV total antibody (anti-HAV IgM and IgG) | 0.0% | 100.0% | 28 | 23.5% | 76.5% | 17 | 11.1% | 88.9% | 27 | 100.0% | 0.0% | 1 |
| Hepatitis B virus (HBV) | HBV surface antibody | 3.6% | 96.4% | 28 | 11.8% | 88.2% | 17 | 0.0% | 100.0% | 27 | 0.0% | 100.0% | 1 |
| Hepatitis B virus (HBV) | HBV surface antigen | 0.0% | 100.0% | 28 | 0.0% | 100% | 17 | 0.0% | 100.0% | 27 | 0.0% | 100.0% | 1 |
| Hepatitis B virus (HBV) | HBV core antibody | 0.0% | 100.0% | 28 | 5.9% | 94.1% | 17 | 0.0% | 100.0% | 27 | 0.0% | 100.0% | 1 |
| Hepatitis C virus (HCV) | Hepatitis C antibody | 0.0% | 100.0% | 28 | 0.0% | 100.0% | 17 | 0.0% | 100.0% | 27 | 0.0% | 100.0% | 1 |
| Herpes simplex virus (HSV) type 1 (HSV-1) | HSV-1 IgG | 32.1% | 67.9% | 28 | 64.7% | 35.3% | 17 | 37.0% | 63.0% | 27 | 100.0% | 0.0% | 1 |
| Herpes simplex virus (HSV) type 2 (HSV-2) | HSV-2 IgG | 14.3% | 85.7% | 28 | 29.4% | 70.6% | 17 | 3.7% | 96.3% | 27 | 0.0% | 100.0% | 1 |
| Human herpesvirus 6 (HHV-6) | HHV-6 IgG | 100.0% | 0.0% | 28 | 76.5% | 23.5% | 17 | 92.6% | 7.4% | 27 | 100.0% | 0.0% | 1 |
| Human polyomavirus 2 (JC virus) | JC virus IgG | 85.7% | 14.3% | 28 | 88.2% | 11.8% | 17 | 96.3% | 3.7% | 27 | 100.0% | 0.0% | 1 |
| Human T-lymphotropic virus (HTLV)-1 | HTLV-1 IgG | 0.0% | 100.0% | 28 | 0.0% | 100.0% | 17 | 0.0% | 100.0% | 27 | 0.0% | 100.0% | 1 |
| Human T-lymphotropic virus (HTLV)-2 | HTLV-2 IgG | 0.0% | 100.0% | 28 | 0% | 100.0% | 17 | 0.0% | 100.0% | 27 | 0.0% | 100.0% | 1 |
| HIV | 5th generation IgG with reflex ELISA | 0.0% | 100.0% | 28 | 0% | 100.0% | 17 | 0.0% | 100.0% | 27 | 0.0% | 100.0% | 1 |
| Strongyloides stercoralis | S. stercoralis IgG | 0.0% | 100.0% | 28 | 0% | 100.0% | 17 | 0.0% | 100.0% | 27 | 0.0% | 100.0% | 1 |
| Syphilis | RPR, IgM, IgG | 0.0% | 100.0% | 28 | 0% | 100.0% | 17 | 0.0% | 100.0% | 27 | 0.0% | 100.0% | 1 |